Home>Topics>Stocks>Nektar Therapeutics

Nektar Therapeutics NKTR

  1. All
  2. Commentary
  3. Headlines
    1. Biotech Fans Could Have a Hangover


      Thu, 14 May 2015

      points more than the MSCI All-Country World Index. Nearly half of the fund's exposure is in top holding Nektar Therapeutics NKTR , a domestic small-cap firm. Big sector bets and a preference for smaller-cap firms are nothing new for

    2. Five Consensus Views that Could Prove Wrong in 2015


      Tue, 27 Jan 2015

      Technosphere insulin has consistently shown signs that it not only improves upon its struggling predecessor ( Pfizer PFE and Nektar's NKTR Exubera), but also that it has the potential to provide better control of glucose levels than the most advanced forms of injectable

    3. Nektar Therapeutics pain drug for knee arthritis fails study


      Thu, 26 Sep 2013

      (Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial.

    4. Dropping Coverage of Nektar


      Mon, 27 Jul 2009

      We are dropping coverage of Nektar Therapeutics NKTR to focus our resources elsewhere.

    5. Nektar Narrows Loss in 1Q


      Thu, 7 May 2009

      Nektar Therapeutics NKTR reported another quarter of year-over-year revenue decline because of the marketing failure of its inhaled insulin product

    6. Nektar Reports Strong 4Q


      Fri, 20 Mar 2009

      estimate in place after reviewing Nektar Therapeutics ' NKTR fourth-quarter results. Total ..... results from a Phase II study of NKTR -118 in patients with opioid ..... Management has indicated that NKTR -118 will be partnered with another

    7. Nektar Sells Pulmonary Unit


      Tue, 21 Oct 2008

      Nektar Therapeutics NKTR announced today that Novartis NVS will ..... programs, including Amikacin Inhale ( NKTR -061), Ciprofloxacin inhaled powder, and inhaled vancomycin ( NKTR -063). While Nektar wasn't in dire

    8. Nektar's Revenue Drops in 2Q


      Mon, 20 Oct 2008

      After reviewing Nektar's NKTR second-quarter earnings, we are maintaining our fair value estimate. Second-quarter revenue dropped to $40 million from

    9. Nektar Putting Exubera in the Past


      Tue, 22 Jul 2008

      Nektar Therapeutics NKTR has been making strides to move past its Exubera failure, and ..... approval, and two of Nektar's proprietary drug candidates-- NKTR -118 and NKTR -102--have recently produced strong results in Phase I studies

    10. Inhaled Insulin Linked to Cancer


      Wed, 9 Apr 2008

      Nektar Therapeutics NKTR announced Wednesday that an increased risk of lung cancer was associated with its inhaled insulin when compared with the control

    « Prev12Next »
    Content Partners